Antithrombotic therapy for transcatheter structural heart intervention.

Guedeney, Paul; Rodés-Cabau, Josep; Ten Berg, Jurriën M; Windecker, Stephan; Angiolillo, Dominick J; Montalescot, Gilles; Collet, Jean-Philippe (2024). Antithrombotic therapy for transcatheter structural heart intervention. EuroIntervention, 20(16), pp. 972-986. Europa Digital & Publishing 10.4244/EIJ-D-23-01084

Text 174_EIJ-D-23-01084_Guedeney.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Percutaneous transcatheter structural heart interventions have considerably expanded within the last two decades, improving clinical outcomes and quality of life versus guideline-directed medical therapy for patients frequently ineligible for surgical treatment. Transcatheter structural heart interventions comprise valve implantation or repair and also occlusions of the patent foramen ovale, atrial septal defects and left atrial appendage. These procedures expose structural devices to arterial or venous blood flow with various rheological conditions leading to potential thrombotic complications and embolisation. Furthermore, these procedures may concern comorbid patients at high risk of both ischaemic and bleeding complications. This state-of-the-art review provides a description of the device-related thrombotic risk associated with these transcatheter structural heart interventions and of the current evidence-based guidelines regarding antithrombotic treatments. Gaps in evidence for each of the studied transcatheter interventions and the main ongoing trials are also summarised.

Interest & Impact

Downloads

0 since deposited on 19 Aug 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item